Nintedanib Biogaran

Nintedanib, the active ingredient in Nintedanib Biogaran, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease in adult patients. It belongs to the antifibrotic therapeutic class and works by inhibiting multiple receptor tyrosine kinases involved in fibroblast activity.

GNH USA supplies Nintedanib Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union marketing authorisation and is distributed under strict Good Distribution Practice standards.

Nintedanib is an antifibrotic agent that targets pathways involved in pulmonary fibrosis.

- Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves lung capacity and delays worsening. - Progressive fibrosing interstitial lung disease: provides benefit in patients with a progressive phenotype.

Nintedanib may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may occur with or without vomiting. - Vomiting: occasional episodes, usually self‑limiting. - Abdominal pain: discomfort or cramps in the stomach area. - Decreased appetite: reduced desire to eat. - Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects: - Severe liver injury: jaundice, hepatic failure, requires monitoring. - Bleeding events: gastrointestinal or pulmonary hemorrhage. - Cardiovascular events: myocardial infarction or ischemic heart disease. - Perforated ulcer: severe gastrointestinal perforation. - Severe infections: opportunistic or bacterial infections. - Pneumothorax: collapsed lung, especially in advanced disease.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor liver function: obtain baseline ALT/AST and repeat periodically. - Assess cardiovascular risk: review history of ischemic heart disease or arrhythmias. - Evaluate bleeding risk: avoid concomitant use of strong anticoagulants when possible. - Use with caution in gastrointestinal disorders: patients with ulcer disease may need close observation. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Nintedanib may interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticoagulants (e.g., warfarin): increased risk of bleeding.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin, clopidogrel): may enhance bleeding tendency. - P‑gp inhibitors (e.g., verapamil): modest increase in plasma levels. - NSAIDs (e.g., ibuprofen): additive gastrointestinal risk.